Table 1.
Characteristic data of the training cohort and validation cohort.
| Characteristic | Primary cohort(N=565) | Validation cohort(N=333) | P value |
|---|---|---|---|
| Age | 56.48 ± 8.88 | 56.68 ± 9.23 | 0.744 |
| Gender (male/female) |
457(80.9%)/108(19.1%) | 273(82.0%)/60(18.0%) | 0.684 |
| Child-Pugh class(A/B) | 419(74.2%)/146(25.8%) | 263(79.0%)/70(21.0%) | 0.103 |
| Cirrhosis (Yes/No) | 94(16.6%)/471(83.4%) | 46(13.8%)/287(86.2%) | 0.260 |
| BCLC stage(0/A) | 182(32.2%)/383(67.8%) | 120(36.0%)/213(64.0%) | 0.241 |
| Tumor number (Single/multiple) | 325(57.5%)/240(42.5%) | 185(55.6%)/148(44.4%) | 0.566 |
| Tumor size (<3cm/≥3cm) | 358(63.4%)/207(36.6%) | 199(59.8%)/134(40.2%) | 0.283 |
| Lym | 1.83 ± 0.68 | 1.85 ± 0.96 | 0.827 |
| WBC | 4.47 ± 2.73 | 4.24 ± 2.15 | 0.438 |
| PLT | 124.66 ± 40.62 | 127.32 ± 52.72 | 0.294 |
| ALT | 28.15 ± 23.13 | 29.09 ± 13.89 | 0.622 |
| AST | 28.23 ± 12.94 | 30.88 ± 13.89 | 0.126 |
| TBIL | 16.60 ± 10.51 | 16.34 ± 6.38 | 0.253 |
| DBIL | 23.23 ± 11.12 | 21.83 ± 4.14 | 0.562 |
| Alb | 36.56 ± 9.36 | 37.51 ± 4.55 | 0.833 |
| Glob | 28.82 ± 8.67 | 28.47 ± 4.93 | 0.491 |
| γ-GT | 62.08 ± 26.96 | 66.96 ± 32.42 | 0.171 |
| Palb | 156.07 ± 63.5 | 164.54 ± 59.57 | 0.189 |
| PT | 14.55 ± 6.25 | 14.88 ± 1.43 | 0.928 |
| TT | 16.98 ± 5.86 | 14.99 ± 1.88 | 0.217 |
| Fib | 2.57 ± 0.12 | 2.69 ± 0.99 | 0.129 |
BCLC, Barcelona Clinic Liver Cancer; Lym, lymphocytes; WBC, white blood cell; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL: total bilirubin; DBIL, direct bilirubin; Alb, albumin; Glob, Globulin; γ-GT, γ-glutamyl transpeptidase; Palb, prealbumin; PT, prothrombin time; TT, thrombin time; Fib, fibrinogen.